These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7482818)
21. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA Transplant Proc; 1995 Oct; 27(5 Suppl 1):49-57. PubMed ID: 7482821 [No Abstract] [Full Text] [Related]
22. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Hartmann A; Sagedal S; Hjelmesaeth J Transplantation; 2006 Jul; 82(2 Suppl):S15-7. PubMed ID: 16858268 [TBL] [Abstract][Full Text] [Related]
26. How valid are risk factors for chronic transplant failure in renal transplant patients found in the literature with regard to our patients: results of a multivariate analysis. Kapsner T; Schneeberger H; Land W Transplant Proc; 1995 Feb; 27(1):878-80. PubMed ID: 7879217 [No Abstract] [Full Text] [Related]
27. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113 [TBL] [Abstract][Full Text] [Related]
28. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909 [TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir. MacDonald AS; Belitsky P; Cohen A; Lee S Transplant Proc; 1991 Feb; 23(1 Pt 2):1355-6. PubMed ID: 1846463 [No Abstract] [Full Text] [Related]
30. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459 [TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus infection in kidney transplantation: prophylaxis and management. Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286 [No Abstract] [Full Text] [Related]
36. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients. Stratta RJ; Alloway RR; Lo A; Hodge EE; Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376 [TBL] [Abstract][Full Text] [Related]
37. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983 [TBL] [Abstract][Full Text] [Related]
38. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients. Israni A; Krok K; Cohen D; Blumberg E; Bloom RD Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685 [TBL] [Abstract][Full Text] [Related]
39. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]